Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Inovio Pharmaceuticals Stock Quote

Inovio Pharmaceuticals (NASDAQ: INO)

Price as of May 24, 2024, 4:00 p.m. ET

Inovio Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
INO +47.87% -71.88% -22.39% -98%
S&P +27.79% +87.71% +13.41% +349%

Inovio Pharmaceuticals Company Info

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

News & Analysis

The Fool has written over 400 articles on Inovio Pharmaceuticals.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.